Association study of HRAS proto-oncogene single nucleotide polymorphism with schizophrenia and therapeutic response to atypical antipsychotics

doi:10.3969/j.issn.1674-8115.2021.12.010

Abstract

Abstract: Objective

·To investigate the relation of HRAS proto-oncogene (HRAS) polymorphism in rs11246176 with schizophrenia and therapeutic response to atypical antipsychotics in the Chinese Han population.

Methods

·A total of 460 schizophrenia patients with acute attack (case group) and 386 healthy controls (control group) were recruited. The patients were treated with atypical antipsychotics and followed up for 26 weeks. Positive and Negative Syndrome Scale (PANSS) were used to evaluate the patients' conditions at the time of enrollment, and 13 weeks and 26 weeks after enrollment respectively. The reduction rates at 26th week were calculated as the standard for drug efficacy (the reduction rate ≥50% was considered effective, and <50% was considered ineffective), and then the patients were divided into the responder group and the non-responder group. The peripheral blood samples were collected to extract DNA. Rs11246176 was genotyped by using TaqMan assays. SHEsis software and SNPstats software were used to compare the frequency distributions of alleles, genotypes, and genotypes under different genetic models between the case group and the control group as well as between the responder group and the non-responder group. In addition, expression quantitative trait loci (eQTL) analysis was used to explore the difference in HRAS expression in the brain among different rs11246176 genotypes.

Results

·There were no significant differences in the distribution of allelic and genotypic frequencies between the case group and the control group (P>0.05). The frequency of A allele in the responder group was higher than that in the non-responder group (P=0.010). The frequency of AA and AG genotypes in the responder group was higher than that in the non-responder group (P=0.040). The reduction rate of PANSS of the patients with AA or AG genotype 26th week was significantly higher than that of the patients with GG genotype (P=0.010). Furthermore, the brain eQTL analysis revealed that in the dorsolateral prefrontal cortex of normal Caucasians and African Americans, the HRAS mRNA expression level of the AA genotype was the highest, followed by the AG genotype and the GG genotype in the order (P=0.000).

Conclusion

·Rs11246176 polymorphism in HRAS gene is not associated with the occurrence of schizophrenia in the Chinese Han population, but may be related to therapeutic response to atypical antipsychotics. A allele carriers may have better response to atypical antipsychotics.

Key words: schizophrenia, HRAS proto-oncogene, single nucleotide polymorphism (SNP), rs11246176, atypical antipsychotics

CLC Number:

R749.3

Rui LI, Duan ZENG, Shen HE, Yi-feng SHEN, Hua-fang LI. Association study of HRAS proto-oncogene single nucleotide polymorphism with schizophrenia and therapeutic response to atypical antipsychotics[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(12): 1613-1617.

Figures/Tables 5

TrendMD

References 24

1	Deane AR, Potemkin N, Ward RD. Mitogen-activated protein kinase (MAPK) signalling corresponds with distinct behavioural profiles in a rat model of maternal immune activation[J]. Behav Brain Res, 2021, 396: 112876.
2	Stertz L, Di Re J, Pei G, et al. Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients[J]. Neuropsychopharmacology, 2021, 46(3): 673-682.
3	Yu WJ, Fang HW, Zhang L, et al. Reversible changes in BDNF expression in MK-801-induced hippocampal astrocytes through NMDAR/PI3K/ERK signaling[J]. Front Cell Neurosci, 2021, 15: 672136.
4	Haszto CS, Stanley JA, Iyengar S, et al. Regionally distinct alterations in membrane phospholipid metabolism in schizophrenia: a meta-analysis of phosphorus magnetic resonance spectroscopy studies[J]. Biol Psychiatry Cogn Neurosci Neuroimaging, 2020, 5(3): 264-280.
5	Vornholt E, Drake J, Mamdani M, et al. Identifying a novel biological mechanism for alcohol addiction associated with circRNA networks acting as potential miRNA sponges[J]. Addict Biol, 2021, 26(6): e13071.
6	Kang M, Lee YS. The impact of RASopathy-associated mutations on CNS development in mice and humans[J]. Mol Brain, 2019, 12(1): 96.
7	Comings DE, Wu SJ, Chiu C, et al. Studies of the c-Harvey-Ras gene in psychiatric disorders[J]. Psychiatry Res, 1996, 63(1): 25-32.
8	胡国芹, 吕钦谕, 赵静, 等. NOS1AP基因非编码区位点多态性与精神分裂症的关联研究[J]. 上海交通大学学报(医学版), 2021, 41(1): 29-34.
9	阳红, 黄欣欣, 刘超, 等. 突触结合蛋白2基因多态性与中国汉族精神分裂症的关联研究[J]. 上海交通大学学报(医学版), 2021, 41(1): 16-22.
10	李娜, 安宇, 张永录, 等. 中国汉族人群GAD1和GABRB3基因启动子区单核苷酸多态性与精神分裂症的关联研究[J]. 上海交通大学学报(医学版), 2020, 40(3): 310-316.
11	Yu W, Huang J, He S, et al. Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study[J]. Gen Psychiatr, 2021, 34(1): e100289.
12	Leucht S, Samara M, Heres S, et al. Dose equivalents for antipsychotic drugs: the DDD method[J]. Schizophr Bull, 2016, 42(): S90-S94.
13	Schäfer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D₂ receptor gene[J]. Am J Psychiatry, 2001, 158(5): 802-804.
14	Obermeier M, Mayr A, Schennach-Wolff R, et al. Should the PANSS be rescaled?[J]. Schizophr Bull, 2010, 36(3): 455-460.
15	BrainSeq: A Human Brain Genomics Consortium. BrainSeq: neurogenomics to drive novel target discovery for neuropsychiatric disorders[J]. Neuron, 2015, 88(6): 1078-1083.
16	Owen MJ, Sawa A, Mortensen PB. Schizophrenia[J]. Lancet, 2016, 388(10039): 86-97.
17	Gao K, Wang Q, Zhang Y, et al. Association study of VEGFA polymorphisms with schizophrenia in Han Chinese population[J]. Neurosci Lett, 2015, 590: 121-125.
18	NCBI. Rs11246176 reference SNP report[DB/OL]. [2021-09-03]. .
19	Hérault J, Perrot A, Barthélémy C, et al. Possible association of c-Harvey-Ras-1 (HRAS-1) marker with autism[J]. Psychiatry Res, 1993, 46(3): 261-267.
20	Margolis RL, Chuang DM, Post RM. Programmed cell death: implications for neuropsychiatric disorders[J]. Biol Psychiatry, 1994, 35(12): 946-956.
21	Downward J. Ras signalling and apoptosis[J]. Curr Opin Genet Dev, 1998, 8(1): 49-54.
22	Fan S, Meng Q, Laterra JJ, et al. Ras effector pathways modulate scatter factor-stimulated NF-κB signaling and protection against DNA damage[J]. Oncogene, 2007, 26(33): 4774-4796.
23	Lü G, Li L, Wang B, et al. LINC00623/miR-101/HRAS axis modulates IL-1β-mediated ECM degradation, apoptosis and senescence of osteoarthritis chondrocytes[J]. Aging, 2020, 12(4): 3218-3237.
24	Ľupták M, Michaličková D, Fišar Z, et al. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets[J]. World J Psychiatry, 2021, 11(7): 277-296.

Index	Responder group （n=132）	Non-responder group （n=323）	P value
Age/year	48.19±17.26	48.75±13.11	0.741
Male/female/n	63/69	155/168	0.960
Baseline PANSS score/score	77.84±16.13	74.25±15.35	0.071
Onset age/year	26.42±10.18	27.24±11.29	0.474
Disease course/year	18 （5‒32）	21 （8‒33）	0.171
Drug dosage^①/（mg·d^-1）	10.0 （5.0‒15.0）	10.0 （5.0‒14.4）	0.469
Baseline application of drug （users/non-users）/n	97/35	217/106	0.187

Index	Responder group （n=132）	Non-responder group （n=323）	P value
Age/year	48.19±17.26	48.75±13.11	0.741
Male/female/n	63/69	155/168	0.960
Baseline PANSS score/score	77.84±16.13	74.25±15.35	0.071
Onset age/year	26.42±10.18	27.24±11.29	0.474
Disease course/year	18 （5‒32）	21 （8‒33）	0.171
Drug dosage^①/（mg·d^-1）	10.0 （5.0‒15.0）	10.0 （5.0‒14.4）	0.469
Baseline application of drug （users/non-users）/n	97/35	217/106	0.187

Group	Allele/n（%）		χ² value	P value	Genotype/n（%）			χ² value	P value
Group	A	G	χ² value	P value	AA	AG	GG	χ² value	P value
Case group	138 （15.2）	772 （84.8）	0.172	0.400	13 （2.9）	112 （24.6）	330 （72.5）	1.008	0.600
Control group	105 （13.7）	661 （86.3）			11 （2.9）	83 （21.7）	289 （75.5）
Responder group	52 （19.7）	212 （80.3）	5.943	0.010	7 （5.3）	38 （28.8）	87 （65.9）	6.332	0.040
Non-responder group	86 （13.3）	560 （86.7）			6 （1.9）	74 （22.9）	243 （75.2）

Group	Allele/n（%）		χ² value	P value	Genotype/n（%）			χ² value	P value
Group	A	G	χ² value	P value	AA	AG	GG	χ² value	P value
Case group	138 （15.2）	772 （84.8）	0.172	0.400	13 （2.9）	112 （24.6）	330 （72.5）	1.008	0.600
Control group	105 （13.7）	661 （86.3）			11 （2.9）	83 （21.7）	289 （75.5）
Responder group	52 （19.7）	212 （80.3）	5.943	0.010	7 （5.3）	38 （28.8）	87 （65.9）	6.332	0.040
Non-responder group	86 （13.3）	560 （86.7）			6 （1.9）	74 （22.9）	243 （75.2）

Model	OR	95%CI	P value
Codominant			0.670
GG	1.00
AG	0.85	0.56‒1.28
AA	1.20	0.41‒3.47
Dominant			0.520
GG	1.00
AG/AA	0.88	0.59‒1.31
Recessive			0.680
GG/AG	1.00
AA	1.25	0.43‒3.61
Log-additive	0.93	0.66‒1.31	0.680